P-x-x Containing (x Is Chalcogen) Patents (Class 514/109)
  • Patent number: 10064673
    Abstract: A mixing and delivery device for osseous tissue and method of use is provided. A kit for use by a medical professional is also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 4, 2018
    Assignee: KT, LLC
    Inventors: Timothy R. Brahm, Kevin Foley
  • Patent number: 9908909
    Abstract: An object of the present invention is to provide a crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: March 6, 2018
    Assignee: OTSUKA CHEMICAL CO., LTD.
    Inventors: Hiroaki Yuasa, Hiroki Okazaki
  • Patent number: 9907772
    Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: March 6, 2018
    Assignee: Lipopharma Therapeutics, S.L.
    Inventors: Pablo Vicente Escriba Ruiz, Xavier Busquets Xaubet, Maria Laura Martin, Rafael Alvarez Martinez, Victoria Llado Canellas
  • Patent number: 9763906
    Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 19, 2017
    Assignee: Lipopharma Therapeutics S.L.
    Inventors: Pablo Vicente Escriba Ruiz, Xavier Busquets Xaubet, Maria Laura Martin, Rafael Alvarez Martinez, Victoria Llado Canellas
  • Patent number: 9763907
    Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 19, 2017
    Assignee: Lipopharma Therapeutics, S.L.
    Inventors: Pablo Vicente Escriba Ruiz, Xavier Busquets Xaubet, Maria Laura Martin, Rafael Alvarez Martinez, Victoria Llado Canellas
  • Patent number: 9629862
    Abstract: The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 25, 2017
    Assignee: Retrophin, Inc.
    Inventors: Andrew Vaino, Marek Biestek, Martin Shkreli
  • Patent number: 9585849
    Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: March 7, 2017
    Assignee: The Burlington HC Research Group, Inc.
    Inventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
  • Patent number: 9085593
    Abstract: This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 21, 2015
    Assignee: SANSHO CO., LTD.
    Inventors: Kimiko Murofushi, Ikuko Masuda, Toshiro Morohoshi
  • Patent number: 8927526
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: January 6, 2015
    Assignee: Kaneq Pharma Inc.
    Inventors: John Colucci, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • Patent number: 8912124
    Abstract: The invention relates to derivatives of (1-cyanocyclopropyl)phenylphosphinic acid of the formula (I) and to salts thereof, of the formula (II), for enhancing stress tolerance in plants to abiotic stress, preferably to drought stress, especially for enhancing plant growth and/or for increasing plant yield.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: December 16, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Lothar Willms, Hans-Joachim Zeiβ, Marco Busch, Christopher Hugh Rosinger, Ines Heinemann, Isolde Häuser-Hahn, Martin Jeffrey Hills, Pascal Von Koskull-Döring
  • Patent number: 8815227
    Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: August 26, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Patent number: 8809304
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: August 19, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Marukawa, Nobutaka Kobayashi, Kunio Sugahara
  • Patent number: 8716184
    Abstract: A herbicide combination comprising a) at least one herbicide (A) selected from the group consisting of glyphosate (A1) and its agrochemically compatible salts, and glufosinate (A2) and its agrochemically compatible salts, and b) a herbicide (B) which is a hydrate of the compound 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl-(1-methylethyl)amino]sulfonyl]benzamide, and the use thereof for controlling harmful plants.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: May 6, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Alfred Angermann, Stefan Lehr, Hubert Menne, Lothar Willms, Erwin Hacker, Britta Olenik
  • Patent number: 8716363
    Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Globus Medical, Inc.
    Inventor: Vipin Kunjachan
  • Patent number: 8691726
    Abstract: A synergistic antimicrobial composition containing a glyphosate compound and zinc pyrithione is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: April 8, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Emerentiana Sianawati, Sudhakar Balijepalli
  • Patent number: 8673883
    Abstract: The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 18, 2014
    Assignee: Retrophin, Inc.
    Inventors: Andrew Vaino, Marek Biestek, Martin Shkreli
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Publication number: 20130225529
    Abstract: Phospho-ester compounds and pharmaceutical compositions thereof administered by the respiratory and other routes for the prevention and/or treatment of lung and brain cancer and precancerous conditions thereof, for the treatment of pain, for the treatment of skin disorders, for treating and/or preventing inflammation-related diseases, and for the treatment and prevention of cancer.
    Type: Application
    Filed: February 27, 2013
    Publication date: August 29, 2013
    Inventor: Basil RIGAS
  • Patent number: 8492314
    Abstract: The present invention provides a concentrate for dilution with water in the preparation of an agricultural composition for application to crops, soil or animals. The concentrate is recommended for use with agricultural chemicals whose agricultural activity varies with the pH of the water. It comprises an active ingredient and a combination of pH indicators for coloring the water, the pH indicators being selected so as to indicate different colors of spray water at different pH levels. The proportions of active ingredient and pH indicators are selected so that when the concentrate is added to water, the pH indicators indicate visually upper and lower pH limits for optimum activity of the agricultural chemical.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: July 23, 2013
    Assignee: AECI Limited
    Inventors: Hendrik Frederik Greyling, Hugo R Minnaar, Martin D Bloomberg
  • Patent number: 8440787
    Abstract: The present invention provides hydmoxyapatite-targeting, multiarm polymer reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatile-targeting moieties located at the terminus of one or more of the polymer chains. The multiarm polymers are optionally divided or separated by one or more degradable linkages into polymer segments having a molecular weight suitable for renal clearance. The polymeric reagents of the invention can have a substantially linear structure, although branched or multiarm structures are contemplated as well. The invention is suited for applications in which use of a high molecular weight polymer is desired, such as a total polymer number average molecular weight of at least about 30,000 Da for linear polymers and 20,000 Da for multiarm polymers. Each structure includes one or more linkages capable of degradation in vivo.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: May 14, 2013
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Patent number: 8252775
    Abstract: To perform large-scale multiplex analysis of lipid-specific binding, lipid microarrays were developed. Lipids identified as disease associated, or analogs there, can be tolerogenic to patients suffering from autoimmune disease. Lipid array analysis has revealed anti-lipid antibodies in patients with immune disorders, and may contribute to the pathogenesis of disease.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 28, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, U.S. Department of Veteran Affairs
    Inventors: Jennifer L. Kanter, William H. Robinson, Lawrence Steinman
  • Publication number: 20120108550
    Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.
    Type: Application
    Filed: March 15, 2010
    Publication date: May 3, 2012
    Applicant: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO VK
    Inventors: Pablo Vicente Escriba Ruiz, Xavier Busquets Xaubet, Silvia Teres Jimenez, Gwendolyn Barcelo Coblijn, Victoria Llado Canellas, Amaia Marcilla Etxenike, Maria Laura Martin, Monica Higuera Urbano, Rafael Alvarez Martinez, Daniel Horacio Lopez
  • Patent number: 8129361
    Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: March 6, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara
  • Patent number: 8124594
    Abstract: Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels in subjects in need thereof are disclosed herein. The methods can be useful for subjects having age related decline in testosterone, exercise induced decline in testosterone, and/or hypogonadism.
    Type: Grant
    Filed: November 30, 2008
    Date of Patent: February 28, 2012
    Assignee: Chemi Nutra, LLC
    Inventors: Martin Purpura, Ralf Jäger, Scott L. Hagerman
  • Patent number: 8093230
    Abstract: The invention concerns the use of mercaptoethane sulfonate-sodium (Mesna) to increase the solubility of Ifosfamide in storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical preparations, storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical Ifosfamide preparations for parenteral administration as well as a process for their production.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: January 10, 2012
    Assignee: Baxter International Inc.
    Inventor: Berthold Roessler
  • Patent number: 8066971
    Abstract: This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: November 29, 2011
    Assignee: Los Angeles Biomedical Reseach Institute at Harbor UCLA Medical Center
    Inventors: John S. Torday, Virender K. Rehan
  • Publication number: 20110237525
    Abstract: A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.
    Type: Application
    Filed: June 18, 2010
    Publication date: September 29, 2011
    Inventors: Boyd E. Haley, Niladri Narayan Gupta
  • Patent number: 8003630
    Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: August 23, 2011
    Assignee: The Penn State Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Jill P. Smith
  • Patent number: 7939052
    Abstract: Administration of U-II to rats caused an increase in the redness or the skin temperature of the ear of the rats. The increase was inhibited by compounds that decease the biological activity of the U-II/UT receptor. Thus, the present invention provides methods of measuring the biological activity of an U-II receptor by monitoring the redness or the skin temperature of the ear of an animal, and the use of the methods to test compounds for their abilities to increase or decrease the biological activity of an U-II receptor.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 10, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Robert Schulingkamp, Jianshen Qi, Raymond Colburn, Dennis Stone, Christopher Van Besien, Lisa Minor, Patricia Andrade-Gordon, Bruce Damiano
  • Publication number: 20100099742
    Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.
    Type: Application
    Filed: November 30, 2009
    Publication date: April 22, 2010
    Inventors: Giorgio Stassi, Matilde Todaro
  • Patent number: 7550449
    Abstract: It is an object of the present invention to synthesize a carba cyclic phosphatidic acid derivative having a novel structure by substituting O at position sn-2 of the glycerol skeleton with CH2, and study the action of the obtained derivative to suppress cancer cell invasion. The present invention provides a compound represented by the following formula (I): wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, wherein these groups may comprise a cycloalkane ring or aromatic ring; and M represents a hydrogen atom or counter cation.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: June 23, 2009
    Inventors: Kimiko Murofushi, Mutsuko Mukai, Susumu Kobayashi, Hiromu Murofushi
  • Patent number: 7488786
    Abstract: This invention discloses a process for producing a polymer by controlled polymerization which comprises polymerizing at least one monomer in the presence of a free radical control agent of the structural formula: (Z)-(R1)n, wherein n represents an integer from 1 to about 6; wherein Z represents an aromatic or aliphatic moiety containing from 1 to about 20 carbon atoms; wherein R1 represents a moiety of the structural formula: wherein R2 represents a moiety selected from the group consisting of alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups; wherein the alky groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups can be substituted, unsubstituted, linear, branched or cyclic; and wherein Ar represents a p-alkoxyphenyl group having an alkoxy moiety that contains from 1 to 8 carbon atoms.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 10, 2009
    Assignee: The Goodyear Tire & Rubber Company
    Inventor: Dane Kenton Parker
  • Publication number: 20090022831
    Abstract: Use of Fructus schisandrae in preparation of medicaments for preventing and reducing toxicity and side effects of antineoplastic agents. The toxicity and side effects of antineoplastic agents are cardiovascular toxicity, hepatotoxicity, nephrotoxicity, suppression of bone marrow, immunosuppression, or alopecia etc induced by antineoplastic agents. Fructus schisandrae and extracts thereof, especially ethanol extracts, schisandrin B, are effective in reducing antineoplastic agent's toxicity and side effects.
    Type: Application
    Filed: February 7, 2008
    Publication date: January 22, 2009
    Inventor: Xun Hu
  • Publication number: 20080317834
    Abstract: The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.
    Type: Application
    Filed: November 10, 2003
    Publication date: December 25, 2008
    Applicant: Neurochem (International) Limited
    Inventors: Allan M. Green, Francine Gervais
  • Patent number: 7462674
    Abstract: This invention discloses a process for producing a polymer by controlled polymerization which comprises polymerizing at least one monomer in the presence of a free radical control agent of the structural formula: (Z)-(R1)n, wherein n represents an integer from 1 to about 6; wherein Z represents an aromatic or aliphatic moiety containing from 1 to about 20 carbon atoms; wherein R1 represents a moiety of the structural formula: wherein R2 represents a moiety selected from the group consisting of alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups; wherein the alky groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, and alkaryl groups can be substituted, unsubstituted, linear, branched or cyclic; and wherein Ar represents a p-alkoxyphenyl group having an alkoxy moiety that contains from 1 to 8 carbon atoms.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: December 9, 2008
    Assignee: The Goodyear Tire & Rubber Company
    Inventor: Dane Kenton Parker
  • Publication number: 20080286352
    Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components. After a desired liposome biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the liposomes.
    Type: Application
    Filed: August 31, 2006
    Publication date: November 20, 2008
    Inventors: Saran Kumar, Wenlei Jiang, Jorg Ogorka, Jia-ai Zhang
  • Publication number: 20080262286
    Abstract: A method for increasing the radiosensitivity of a target tissue in a subject is disclosed. In some embodiments, the methods includes administering a cytosolic phospholipase A2 (cPLA2) antagonist to the subject, whereby the radiosensitivity of the target tissue is increased. Also disclosed are methods for suppressing tumor growth in a subject and methods for inhibiting tumor blood vessel growth.
    Type: Application
    Filed: April 7, 2008
    Publication date: October 23, 2008
    Inventors: Dennis E. Hallahan, Eugenia M. Yazlovitskaya
  • Publication number: 20080227683
    Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.
    Type: Application
    Filed: February 8, 2005
    Publication date: September 18, 2008
    Applicant: DEFIANTE FARMACEUTICA LDA
    Inventors: Gianfranco Peluso, Menotti Calvani
  • Publication number: 20080160060
    Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 3, 2008
    Applicant: OSTEOGENEX INC.
    Inventor: Debra L. Ellies
  • Publication number: 20080125400
    Abstract: A therapeutically effective amount of at least one phosphoenolpyruvate derivative having Formula (1): wherein: X is selected from the group consisting of O; and NH; Y is selected from the group consisting of OH; OR1; and NR2R3; Z1 and Z2 are selected, independently, from the group consisting of OH; OR4; and NR5R6; and wherein: R1 to R6 are selected, independently, from the group consisting of H; alkyl; cycloalkyl; alkenyl; aryl; and aralkyl, or a physiologically acceptable salt thereof is administered to a patient to reduce or inhibit necrosis of cardiac muscle tissue as evidenced by a reduction in the levels of cardiac troponins in the blood. A particularly preferred derivative is phosphoenolpyruvic amide (“PEPA”), i.e. wherein X?O; Y?NH2; and Z1=Z2=OH.
    Type: Application
    Filed: November 27, 2006
    Publication date: May 29, 2008
    Inventor: Christopher Speirs
  • Publication number: 20080113945
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: August 20, 2007
    Publication date: May 15, 2008
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • Publication number: 20080025949
    Abstract: This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.
    Type: Application
    Filed: July 31, 2006
    Publication date: January 31, 2008
    Inventor: Rashida A. Karmali
  • Publication number: 20080003225
    Abstract: A method is provided for enhancing ADCC in an individual in need thereof, comprising the administration of T lymphocytes expressing a CD16-like receptor in said individual. Said method for enhancing ADCC may be used to treating cancers, autoimmune diseases or infections.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 3, 2008
    Inventors: Henri Vie, Beatrice Clemenceau
  • Publication number: 20070292433
    Abstract: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.
    Type: Application
    Filed: June 15, 2006
    Publication date: December 20, 2007
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, David Y. Liu, Stephen J. Klaus
  • Publication number: 20070249647
    Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.
    Type: Application
    Filed: April 25, 2007
    Publication date: October 25, 2007
    Inventors: David L. Vander Jagt, Lorraine M. Deck
  • Publication number: 20070207486
    Abstract: A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(?251); (ii) VEGF(936); or (iii) AM (3? CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(?251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3? CA repeats.
    Type: Application
    Filed: March 2, 2007
    Publication date: September 6, 2007
    Inventor: Heinz-Josef Lenz
  • Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7176192
    Abstract: This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: February 13, 2007
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventor: Frederick H. Hausheer
  • Patent number: 7163703
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: January 16, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 6906047
    Abstract: This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: June 14, 2005
    Assignee: Gensia Sicor Pharmaceuticals, Inc.
    Inventors: Dorla Mirejovsky, Michael Burkhart